WuXi AppTec acquires gene therapy organization

March 2, 2021

UK-based OXGENE designs and develops scalable gene therapy technologies

WuXi AppTec, a provider of R&D- and manufacturing-enabling services in the pharma, biotech and medical device industries, has completed the acquisition of OXGENE, a UK-based contract research and development organization that designs gene therapy technologies. This deal allows WuXi AppTec to offer support in the design and development of cell and gene therapies for patients in need.

OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec's cell and gene therapy contract testing, development and manufacturing organization (CTDMO) business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing and commercialization of cell and gene therapy products, and accelerate their time to market. OXGENE, which will keep its name, will be WuXi ATU's first facility in Europe.